China's Sinopharm offers experimental COVID-19 vaccines to students - WSJ
Oct 14 (Reuters) - A division of Chinese state-run Sinopharm Group Co Ltd 1099.HK that is developing two COVID-19 vaccines is offering them for free to Chinese students going abroad for higher studies, the Wall Street Journal reported on Wednesday.
The move by China National Biotec Group Co (CNBG) is aimed at boosting public confidence in homegrown inoculations, the Journal reported, citing a company website and some students who applied for it.
The announcement of the company distributing vaccines to students appeared on a website where people could sign up to receive it, the newspaper reported.
The website said on Monday that 481,613 people had taken the vaccine while an additional 93,653 had applied to be inoculated, according to the report.
The website was down starting Tuesday, the report said, adding that it was "under maintenance".
CNBG did not immediately respond to Reuters request for comment.
China launched a vaccine emergency use programme in July, offering three experimental shots developed by a unit of state pharmaceutical giant China National Pharmaceutical Group and U.S.-listed Sinovac Biotech SVA.O.
A fourth vaccine being developed by CanSino Biologics 6185.HK was approved for use by the Chinese military in June.
On the other hand, an Abu Dhabi-based artificial intelligence and cloud computing company called Group 42 is nearing the end of Phase III clinical trials of a vaccine in partnership with CNBG.
(Reporting by Vishal Vivek in Bengaluru; Editing by Subhranshu Sahu)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.